Clinton E Canal
Overview
Explore the profile of Clinton E Canal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
516
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vu M, Butters B, Canal C, Figueroa X
Electromagn Biol Med
. 2024 Oct;
43(4):328-336.
PMID: 39435614
Results from clinical trials show that serotonergic psychedelics have efficacy in treating psychiatric disorders, where currently approved pharmacotherapies are inadequate. Developing psychedelic medicines, however, comes with unique challenges, such as...
2.
Obeng S, Crowley M, Mottinelli M, Leon F, Zuarth Gonzalez J, Chen Y, et al.
Eur J Pharmacol
. 2024 Jul;
980:176863.
PMID: 39068978
Mitragynine, an alkaloid present in the leaves of Mitragyna speciosa (kratom), has a complex pharmacology that includes low efficacy agonism at μ-opioid receptors (MORs). This study examined the activity of...
3.
Varty G, Canal C, Mueller T, Hartsel J, Tyagi R, Avery K, et al.
J Med Chem
. 2024 Apr;
67(8):6144-6188.
PMID: 38593423
Structure-activity studies of 4-substituted-2,5-dimethoxyphenethylamines led to the discovery of 2,5-dimethoxy-4-thiotrifluoromethylphenethylamines, including CYB210010, a potent and long-acting serotonin 5-HT receptor agonist. CYB210010 exhibited high agonist potency at 5-HT and 5-HT receptors,...
4.
Saraf T, Chen Y, Tyagi R, Canal C
Neuropharmacology
. 2023 Nov;
245:109774.
PMID: 37923121
There are no approved pharmacotherapies for fragile X syndrome (FXS), a rare neurodevelopmental disorder caused by a mutation in the FMR1 promoter region that leads to various symptoms, including intellectual...
5.
Tyagi R, Saraf T, Canal C
ACS Pharmacol Transl Sci
. 2023 Oct;
6(10):1480-1491.
PMID: 37854624
The serotonergic psychedelic psilocybin shows efficacy in treating neuropsychiatric disorders, though the mechanism(s) underlying its therapeutic effects remain unclear. We show that a similar psychedelic tryptamine, ,-dipropyltryptamine (DPT), completely prevents...
6.
Saraf T, McGlynn R, Bhatavdekar O, Booth R, Canal C
ACS Chem Neurosci
. 2022 Dec;
13(24):3629-3640.
PMID: 36473166
There are no approved medicines for fragile X syndrome (FXS), a monogenic, neurodevelopmental disorder. Electroencephalogram (EEG) studies show alterations in resting-state cortical EEG spectra, such as increased gamma-band power, in...
7.
Casey A, Cui M, Booth R, Canal C
Biochem Pharmacol
. 2022 Apr;
200:115028.
PMID: 35381208
Blockade of the serotonin 5-HT G protein-coupled receptor (5-HTR) is a fundamental pharmacological characteristic of numerous antipsychotic medications, which are FDA-approved to treat schizophrenia, bipolar disorder, and as adjunctive therapies...
8.
Armstrong J, Saraf T, Bhatavdekar O, Canal C
Epilepsy Res
. 2022 Mar;
182:106891.
PMID: 35290907
The prevalence of seizures in individuals with fragile X syndrome (FXS) is ~25%; however, there are no reports of spontaneous seizures in the Fmr1 knockout mouse model of FXS. Herein,...
9.
Canal C, Leopoldo M
ACS Chem Neurosci
. 2022 Jan;
13(2):185-186.
PMID: 34989567
The molecular characterization of bioactive molecules, for example, small molecules targeting G-protein-coupled receptors, is evolving in complexity, impacting the meaning of terms like "agonist", "antagonist", and "selective", which, in the...
10.
Leon F, Obeng S, Mottinelli M, Chen Y, King T, Berthold E, et al.
J Med Chem
. 2021 Sep;
64(18):13510-13523.
PMID: 34467758
Kratom alkaloids have mostly been evaluated for their opioid activity but less at other targets that could contribute to their physiological effects. Here, we investigated the in vitro and in...